<DOC>
	<DOCNO>NCT03022461</DOCNO>
	<brief_summary>The purpose clinical investigation report long term survival incidence adverse event patient implant HM3 CE Mark Study continue ongoing HeartMate 3 LVAS CE Mark Study 2 year follow-up . The study single arm , prospective , multi-center , non-blinded non-randomized study , intend report long term use HeartMate 3 LVAS patient complete 2-year follow-up HeartMate 3 CE Mark study .</brief_summary>
	<brief_title>HeartMate 3 CE Mark Study Long Term Follow-up</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Patient legal representative sign Informed Consent Form ( ICF ) . 2 . Patient enrol HeartMate 3 CE Mark Study continue support HeartMate 3 LVAS 2 year CE Mark study followup . 1 . Patient consent continue data collection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Ventricular Dysfunction</keyword>
	<keyword>Cardiomyopathies</keyword>
	<keyword>Heart Disease</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Heart-assist Devices</keyword>
	<keyword>Thoratec Corporation</keyword>
</DOC>